Review
Environmental Sciences
Oliwia Zakerska-Banaszak, Liliana Lykowska-Szuber, Michal Walczak, Joanna Zuraszek, Aleksandra Zielinska, Marzena Skrzypczak-Zielinska
Summary: The effectiveness of thiopurine drugs in inflammatory bowel disease (IBD) has been confirmed for more than 50 years. Despite controversies over their cytotoxic properties and adverse effects, thiopurines are still widely used for maintaining remission in Crohn's disease and ulcerative colitis. Further research is needed to explore the modulation of thiopurine action in combination therapy and their interaction with the gut microbiota.
Article
Gastroenterology & Hepatology
Martina Crepaldi, Daria Maniero, Alessandro Massano, Margherita Pavanato, Brigida Barberio, Edoardo Vincenzo Savarino, Fabiana Zingone
Summary: There is no consensus on the recommended duration of and optimal time to stop azathioprine (AZA) therapy in inflammatory bowel disease (IBD). This study analyzed data from IBD patients who discontinued AZA therapy and found that the timing of cessation and stopping point can affect the risk of disease relapse.
WORLD JOURNAL OF GASTROENTEROLOGY
(2023)
Article
Pediatrics
Maria Hemming-Harlo, Laura Merras-Salmio, Anne Nikkonen, Kaija-Leena Kolho
Summary: This study investigated the trough levels of vedolizumab (VDZ) in a pediatric population with inflammatory bowel disease (IBD) in a real-life setting. The results showed that trough levels of VDZ were not associated with clinical remission or continuation of treatment, while a positive response on gut inflammation after induction predicted the need for maintenance therapy.
EUROPEAN JOURNAL OF PEDIATRICS
(2023)
Article
Gastroenterology & Hepatology
Laurie Keefer, Alyse Bedell, Christine Norton, Ailsa L. Hart
Summary: Early diagnosis and optimal control of inflammation are best practices for managing inflammatory bowel disease. Patients often experience challenging symptoms, such as abdominal pain, fatigue, depression, and anxiety, that are not properly addressed. This review highlights the burden of these symptoms, suggests assessment methods, and emphasizes the importance of acknowledging and validating patient's symptoms.
Review
Biochemistry & Molecular Biology
Vishal Khatri, Ramaswamy Kalyanasundaram
Summary: This review focuses on the association between IBD and gut inflammasome, as well as recent advances in research and therapeutic strategies for IBD, discussing inflammasomes and their components, outcomes from experimental animals and human studies, inflammasome inhibitors, and developments in inflammasome-targeted therapies for IBD.
Review
Biochemistry & Molecular Biology
HyunTaek Jung, Jae Seok Kim, Keum Hwa Lee, Kalthoum Tizaoui, Salvatore Terrazzino, Sarah Cargnin, Lee Smith, Ai Koyanagi, Louis Jacob, Han Li, Sung Hwi Hong, Dong Keon Yon, Seung Won Lee, Min Seo Kim, Paul Wasuwanich, Wikrom Karnsakul, Jae Il Shin, Andreas Kronbichler
Summary: Inflammatory bowel disease (IBD) is a chronic inflammatory disease of the gastrointestinal tract that mainly affects young people. Recent studies have shown that microRNAs (miRNAs) play an important role in the pathogenesis, diagnosis, and treatment of IBD.
INTERNATIONAL JOURNAL OF BIOLOGICAL SCIENCES
(2021)
Article
Biology
Lukasz Mokros, Danuta Domzal-Magrowska, Tadeusz Pietras, Kasper Sipowicz, Renata Talar-Wojnarowska
Summary: This study explored the differences between patients with UC and CD regarding chronotype, temperament and depression, and found that CD patients had higher Sensory Sensitivity scores, while emotional reactivity and endurance scores were higher among women with CD. Chronotype was correlated with various temperament traits and predicted disease activity in patients with IBD.
Article
Gastroenterology & Hepatology
Uma Mahadevan, Millie D. Long, Sunanda Kane, Abhik Roy, Marla C. Dubinsky, Bruce E. Sands, Russell D. Cohen, Christina D. Chambers, William J. Sandborn
Summary: The study found that exposure to biologic, thiopurine, or combination therapy during pregnancy did not increase adverse maternal or fetal outcomes, and these treatments can be continued throughout pregnancy for women with IBD to maintain disease control.
Article
Medicine, General & Internal
Silvia Salvatori, Francesco Baldassarre, Michelangela Mossa, Giovanni Monteleone
Summary: Long COVID is common in patients with inflammatory bowel diseases (IBD), with fatigue being the most frequent symptom. It does not influence the frequency of IBD relapses, but is more prevalent in female patients.
JOURNAL OF CLINICAL MEDICINE
(2021)
Review
Gastroenterology & Hepatology
Thomas M. Goodsall, Tran M. Nguyen, Claire E. Parker, Christopher Ma, Jane M. Andrews, Vipul Jairath, Robert Bryant
Summary: The study systematically identified ultrasound scoring indices for assessing inflammatory bowel disease activity, with common components including bowel wall thickness, colour Doppler imaging, and bowel wall stratification. The correlation between ultrasound indices and reference standards, as well as sensitivity, specificity, accuracy, and other properties, varied within certain ranges. However, reliability and responsiveness data were limited, and most studies were rated with unclear or high risk of bias.
JOURNAL OF CROHNS & COLITIS
(2021)
Review
Medicine, General & Internal
Katarzyna Akutko, Andrzej Stawarski
Summary: Inflammatory bowel diseases (IBD) are chronic inflammatory diseases of the digestive tract with periods of remission and relapses. The etiopathogenesis is not fully understood, leading to only symptomatic treatment. There is a constant need to search for new high safety profile therapies for IBD.
JOURNAL OF CLINICAL MEDICINE
(2021)
Article
Medicine, General & Internal
Marie Truyens, Elodie De Ruyck, Gerard Bryan Gonzales, Simon Bos, Debby Laukens, Martine De Vos
Summary: This study showed a high prevalence of fatigue among IBD patients, with approximately half of patients experiencing fatigue even in remission. Female sex, transferrin saturation, and medication were identified as significant factors associated with physical fatigue.
JOURNAL OF CLINICAL MEDICINE
(2021)
Article
Gastroenterology & Hepatology
A. Buisson, M. Nachury, M. Bazoge, C. Yzet, P. Wils, M. Dodel, D. Coban, B. Pereira, M. Fumery
Summary: Switching from intravenous to subcutaneous infliximab can reduce the long-term risk of relapse in patients with inflammatory bowel disease. Close monitoring and dose escalation should be recommended for patients receiving different doses.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS
(2023)
Review
Biotechnology & Applied Microbiology
Guihua Chen, Jun Shen
Summary: Inflammatory bowel disease (IBD) is a global disease with high morbidity and medical costs. Early diagnosis and intervention are crucial for controlling its progression.
FRONTIERS IN BIOENGINEERING AND BIOTECHNOLOGY
(2021)
Article
Gastroenterology & Hepatology
Jurij Hanzel, Peter Bossuyt, Valerie Pittet, Mark Samaan, Monika Tripathi, Wladyslawa Czuber-Dochan, Johan Burisch, Salvatore Leone, Roberto Saldana, Filip Baert, Uri Kopylov, Susanna Jaghult, Michel Adamina, Naila Arebi, Krisztina Gecse
Summary: This study aimed to develop a core outcome set for real-world studies in adult patients with inflammatory bowel disease (IBD). Candidate outcomes and outcome measures were identified through a systematic review and a modified Delphi consensus process. The international panel agreed on the final core outcome set, which will facilitate the synthesis and generation of real-world evidence.
JOURNAL OF CROHNS & COLITIS
(2023)
Article
Gastroenterology & Hepatology
Ruben J. Colman, Andrea Portocarrero-Castillo, Deepika Chona, Jennifer Hellmann, Phillip Minar, Michael J. Rosen
Summary: For pediatric patients with inflammatory bowel disease, initiating treatment with an immunomodulator (IM) for significant ADAs levels can lead to longer durability of anti-TNF and a higher likelihood of achieving steroid-free clinical and biochemical remission on the same anti-TNF. Patients not treated with an IM were unlikely to reverse ADAs levels above 329 ng/mL.
INFLAMMATORY BOWEL DISEASES
(2021)
Article
Gastroenterology & Hepatology
John L. Lyles, Aditi A. Mulgund, Laura E. Bauman, Weizhe Su, Lin Fei, Deepika L. Chona, Puneet Sharma, Renee K. Etter, Jennifer Hellmann, Lee A. Denson, Phillip Minar, Dana M. Dykes, Michael J. Rosen
Summary: A practice-wide proactive anti-TNF TDM QI program improved key clinical outcomes at an academic pediatric gastroenterology practice, including sustained clinical remission, incidence of high titer ADA, and anti-TNF cessation related to ADA.
INFLAMMATORY BOWEL DISEASES
(2021)
Article
Gastroenterology & Hepatology
Ruben J. Colman, Yi-Ting Tsai, Kimberly Jackson, Brendan M. Boyle, Joshua D. Noe, Jeffrey S. Hyams, Geert R. A. M. D'Haens, Johan van Limbergen, Michael J. Rosen, Lee A. Denson, Phillip Minar
Summary: This study identified cut points for LCT and nCD64 associated with FCP remission and found a relationship between clinical response to IFX and biomarkers. Achieving higher IFX trough levels was associated with greater improvement in FCP and nCD64.
INFLAMMATORY BOWEL DISEASES
(2021)
Article
Pharmacology & Pharmacy
Ye Xiong, Tomoyuki Mizuno, Ruben Colman, Jeffrey Hyams, Joshua D. Noe, Brendan Boyle, Yi-Ting Tsai, Min Dong, Kimberly Jackson, Nieko Punt, Michael J. Rosen, Lee A. Denson, Alexander A. Vinks, Phillip Minar
Summary: The study identified blood biomarkers for rapid clearance and exposure targets of infliximab in pediatric Crohn's disease. Higher AUC during induction was associated with better treatment outcomes and lower surgery rates for patients.
CLINICAL PHARMACOLOGY & THERAPEUTICS
(2021)
Article
Medicine, Research & Experimental
Rishi S. Mehta, Zachary L. Taylor, Lisa J. Martin, Michael J. Rosen, Laura B. Ramsey
Summary: This study found an association between SLCO1B1 *15 allele and MTX-induced nausea in pediatric patients with IBD. Patients with the *15 allele may benefit from a reduction in MTX dose to reduce exposure and treatment initiation with concomitant ondansetron to alleviate nausea.
CTS-CLINICAL AND TRANSLATIONAL SCIENCE
(2022)
Review
Gastroenterology & Hepatology
Babajide A. Ojo, Kelli L. VanDussen, Michael J. Rosen
Summary: Physiological, molecular, and genetic findings suggest that impaired intestinal epithelial function is a key element in the development of ulcerative colitis (UC). However, the lack of therapies targeting the epithelium is a weakness in UC treatment. The absence of preclinical human models of UC hinders drug discovery.
INFLAMMATORY BOWEL DISEASES
(2022)
Article
Gastroenterology & Hepatology
Ruben J. Colman, Ye Xiong, Tomoyuki Mizuno, Jeffrey S. Hyams, Joshua D. Noe, Brendan Boyle, Geert R. D'Haens, Johan van Limbergen, Kelly Chun, Jane Yang, Michael J. Rosen, Lee A. Denson, Alexander A. Vinks, Phillip Minar
Summary: This study evaluated the impact of ATI on infliximab clearance and loss of response, finding that even low levels of ATI can affect drug clearance. The data suggest that dose optimization for low-level ATI can improve infliximab clearance and prevent loss of response.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS
(2022)
Editorial Material
Gastroenterology & Hepatology
Michael J. Rosen
Article
Gastroenterology & Hepatology
Michael J. Duryee, Rizwan Ahmad, Derrick D. Eichele, Carlos D. Hunter, Ananya Mitra, Geoffrey A. Talmon, Shailender Singh, Lynette M. Smith, Michael J. Rosen, Punita Dhawan, Geoffrey M. Thiele, Amar B. Singh
Summary: This study found that circulating IgG anti-MAA antibody levels can serve as a novel, noninvasive, and highly sensitive test to identify patients with UC and possibly differentiate them from patients with CD.
CLINICAL AND TRANSLATIONAL GASTROENTEROLOGY
(2022)
Article
Gastroenterology & Hepatology
Kathryn Clarkston, Rebekah Karns, Anil G. Jegga, Mihika Sharma, Sejal Fox, Babajide A. Ojo, Phillip Minar, Thomas D. Walters, Anne M. Griffiths, David R. Mack, Brendan Boyle, Neal S. LeLeiko, James Markowitz, Joel R. Rosh, Ashish S. Patel, Sapana Shah, Robert N. Baldassano, Marian Pfefferkorn, Cary Sauer, Subra Kugathasan, Yael Haberman, Jeffrey S. Hyams, Lee A. Denson, Michael J. Rosen
Summary: This study aimed to predict clinical outcomes in pediatric ulcerative colitis (UC) through assessing gene expression and investigate the potential pathogenic roles of predictive genes. IL13RA2 was associated with corticosteroid-free remission, while RORC was associated with a lower likelihood of colectomy. RNA sequencing and immunostaining supported these findings.
JOURNAL OF CROHNS & COLITIS
(2022)
Article
Gastroenterology & Hepatology
Kaitlin G. Whaley, Ye Xiong, Rebekah Karns, Jeffrey S. Hyams, Subra Kugathasan, Brendan M. Boyle, Thomas D. Walters, Judith Kelsen, Neal LeLeiko, Jason Shapiro, Amanda Waddell, Sejal Fox, Ramona Bezold, Stephanie Bruns, Robin Widing, Yael Haberman, Margaret H. Collins, Tomoyuki Mizuno, Phillip Minar, Geert R. D'Haens, Lee A. Denson, Alexander A. Vinks, Michael J. Rosen
Summary: This study aimed to model the pharmacokinetics of infliximab (IFX) in pediatric acute severe ulcerative colitis (ASUC) and assess the association between IFX exposure and clinical response. The results showed that IFX exposure was not predictive of clinical outcomes in pediatric ASUC, and a higher initial dose may optimize early outcomes.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY
(2023)
Article
Gastroenterology & Hepatology
Michael A. Schumacher, Cambrian Y. Liu, Kay Katada, Megan H. Thai, Jonathan J. Hsieh, Britany J. Hansten, Amanda Waddell, Michael J. Rosen, Mark R. Frey
Summary: This study found that Sprouty2 limits the differentiation of colonic deep crypt secretory (DCS) cells by suppressing the IL13 signaling pathway. The DCS cells express high levels of the antimicrobial peptide RELM beta in homeostasis. Loss of Sprouty2 leads to the release of IL13, promoting the proliferation of DCS cells and increased levels of colonic RELM beta.
CELLULAR AND MOLECULAR GASTROENTEROLOGY AND HEPATOLOGY
(2023)
Article
Medicine, Research & Experimental
Tzipi Braun, Katya E. Sosnovski, Amnon Amir, Marina BenShoshan, Kelli L. VanDussen, Rebekah Karns, Nina Levhar, Haya Abbas-Egbariya, Rotem Hadar, Gilat Efroni, David Castel, Camila Avivi, Michael J. Rosen, Anne M. Grifiths, Thomas D. Walters, David R. Mack, Brendan M. Boyle, Syed Asad Ali, Sean R. Moore, Melanie Schirmer, Ramnik J. Xavier, Subra Kugathasan, Anil G. Jegga, Batya Weiss, Chen Mayer, Iris Barshack, Shomron Ben-Horin, Igor Ulitsky, Anthony Beucher, Jorge Ferrer, Jeffrey S. Hyams, Lee A. Denson, Yael Haberman
Summary: This study analyzes patient data to identify dysregulation of long noncoding RNAs (lncRNAs) in inflammatory bowel diseases. The HNF1A-AS1 lncRNA is found to be reduced in ulcerative colitis and associated with disease severity. These findings provide potential targets for future preclinical studies.
Article
Gastroenterology & Hepatology
Eileen Crowley, Christopher Ma, Leonard Guizzetti, Guangyong Zou, Peter J. Lewindon, Michael S. Gee, Jeffrey S. Hyams, Michael J. Rosen, Daniel von Allmen, Anthony de Buck van Overstraeten, Lisa M. Shackelton, Julie Remillard, Lauren Schleicher, Jonathan R. Dillman, Jordi Rimola, Stuart A. Taylor, Joel G. Fletcher, Peter C. Church, Brian G. Feagan, Anne M. Griffiths, Vipul Jairath, Mary-Louise C. Greer
Summary: This study aims to determine the appropriateness of MRI-based disease activity indices, assessment methods, and clinical trial design for pediatric perianal fistulizing CD. The findings suggest that existing indices can be adapted and used for children, and further research is needed to assess their operating properties in a pediatric patient population.
INFLAMMATORY BOWEL DISEASES
(2023)
Article
Gastroenterology & Hepatology
Temara M. Hajjat, Maua Mosha, Kaitlin G. Whaley, Michael J. Rosen, Carmine Suppa, James Markowitz, Lauren Dufour, Cary Sauer, Monica Shukla-Udawatta, Brendan Boyle, Meghan Gibson, Jason Shapiro, Derica Sams, Francisco Sylvester, Gabriele Hunter, Maria E. Perez, Jeffrey S. Hyams
Summary: This study retrospectively examined the 1-year outcomes of vedolizumab therapy in 159 pediatric patients with IBD, finding that approximately 43% achieved corticosteroid-free clinical remission at 1 year. Vedolizumab was shown to be safe and effective in this pediatric population, with no infusion reactions or serious side effects noted.
CROHNS & COLITIS 360
(2021)